FDA flags 19 deaths in Ocaliva patients, putting Intercept's NASH bid in doubt
admin 22nd September 2017 Uncategorised 0Intercept has been the presumed leader in a race toward one of the hottest new markets in pharma, the liver disease NASH. But 19 deaths in current Ocaliva patients pose a threat to those hopes, and the med faces a setback in its now-approved indication, too.
More: FDA flags 19 deaths in Ocaliva patients, putting Intercept's NASH bid in doubt
Source: fierce